2025 ASCO Gastrointestinal Cancers Symposium

QL1706 (PSB205) — Abstract 579

Scientific title:

First-line iparomlimab and tuvonralimab (QL1706) or iparomlimab (QL1604) + bevacizumab (BEV) for unresectable hepatocellular carcinoma (HCC): Updated results from the phase Ib/II DUBHE-H-106 study.